Cipla Ltd, headquartered in Mumbai, India, announced on April 23 that it has received final approval from the US Food and Drug Administration (USFDA) for its generic version of albuterol sulfate inhalation aerosol. This medication is indicated for the treatment and prevention of bronchospasm in patients aged four years and older, including those with reversible obstructive airway disease and exercise-induced bronchospasm. Cipla's product is the first AB-rated generic therapeutic equivalent to Ventolin HFA, which is marketed by GlaxoSmithKline. The approval is seen as a significant achievement for Cipla, showcasing its strong capabilities in developing complex inhalation products. According to IQVIA data, the total market for albuterol in the US is valued at approximately $1.5 billion, indicating substantial potential for Cipla in this segment. This approval not only enhances Cipla's respiratory portfolio but also reinforces its leadership in the albuterol inhalation category, as it already has approved generics for both Ventolin HFA and Proventil HFA.